Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 19% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-09-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal toradiationgreater thanpatient
  Phrases that lowered it: advancedmalecombinationlocallythe investigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Design: single group (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 17.2% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 96.1% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 155 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma NCT02956889 · started 2016 · scored riskier than 69% of active trials terminated
• Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC) NCT02667574 · started 2014 · scored riskier than 56% of active trials completed
• Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma NCT03035188 · started 2017 · scored riskier than 91% of active trials completed
• Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas NCT02639117 · started 2015 · scored riskier than 80% of active trials completed
• Vismodegib for Treatment of Basal Cell Carcinoma NCT01543581 · started 2012 · scored riskier than 45% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.